Press coverage about Apollo Endosurgery (NASDAQ:APEN) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Apollo Endosurgery earned a news impact score of 0.09 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.0254477416352 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
Apollo Endosurgery traded down $0.11, reaching $6.50, on Friday, Marketbeat.com reports. 71,783 shares of the company’s stock were exchanged, compared to its average volume of 61,823. Apollo Endosurgery has a twelve month low of $3.55 and a twelve month high of $8.50. The firm has a market capitalization of $115.74 million, a PE ratio of -3.23 and a beta of 0.40. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.98 and a quick ratio of 1.38.
Apollo Endosurgery (NASDAQ:APEN) last announced its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.07). The business had revenue of $15.74 million for the quarter, compared to analyst estimates of $16.00 million. Apollo Endosurgery had a negative return on equity of 61.61% and a negative net margin of 41.50%. equities research analysts expect that Apollo Endosurgery will post -1.6 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on APEN shares. Zacks Investment Research lowered Apollo Endosurgery from a “hold” rating to a “sell” rating in a report on Tuesday, March 6th. Piper Jaffray Companies started coverage on Apollo Endosurgery in a report on Friday, April 13th. They set an “overweight” rating and a $8.00 price objective on the stock. Finally, ValuEngine raised Apollo Endosurgery from a “sell” rating to a “hold” rating in a report on Monday, May 7th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Apollo Endosurgery currently has a consensus rating of “Buy” and a consensus target price of $9.15.
In other news, CEO Todd Newton bought 72,727 shares of the firm’s stock in a transaction on Wednesday, June 20th. The shares were bought at an average cost of $5.50 per share, for a total transaction of $399,998.50. Following the completion of the transaction, the chief executive officer now owns 268,606 shares in the company, valued at $1,477,333. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Matthew S. Crawford bought 363,500 shares of the firm’s stock in a transaction on Wednesday, June 20th. The shares were purchased at an average price of $5.50 per share, for a total transaction of $1,999,250.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 440,772 shares of company stock worth $2,424,246. 52.80% of the stock is owned by company insiders.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.